BPC-157 + TB-500 Capsules: Oral Blend Guide

BPC-157 + TB-500 capsules combine two healing peptides into a single oral dose. The concept originates from the injectable "wolverine stack," named for the comic-book character's regenerative ability. Vendors adapted the injectable combination into capsule form to offer a needle-free alternative.

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice. It has extensive animal research demonstrating wound healing, GI protection, and anti-inflammatory effects. Oral administration is well-studied: the peptide was originally discovered in the stomach and retains biological activity when taken by mouth (Sikiric et al., Curr Pharm Des, 2011).

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tb4), a 43-amino-acid protein involved in cell migration, angiogenesis, and tissue repair. Tb4 was tested in human clinical trials for chronic wound healing and dry eye, both via injection or topical application (Philp et al., Ann N Y Acad Sci, 2006). Its oral pharmacology remains uncharacterized.

Most capsule products on the market contain 500 mcg of BPC-157 paired with 750 mcg to 1,500 mcg of TB-500. Some use the BPC-157 arginate form; others use acetate. The TB-500 component is typically the acetate salt.

The two peptides target overlapping but distinct phases of tissue repair. Understanding each one's role explains why researchers and users combine them.

Think of wound healing like rebuilding a damaged road. BPC-157 acts as the emergency repair crew: it stabilizes the surface, patches cracks, and restores basic function quickly. It upregulates VEGF (vascular endothelial growth factor) to build new blood vessels to the damaged area and stabilizes nitric oxide production to maintain blood flow (Hsieh et al., Sci Rep, 2020). BPC-157 works from the ground up, excelling at mucosal and connective tissue repair.

TB-500 is the structural engineering team. It promotes actin polymerization, which is the scaffolding that cells use to migrate into wounded areas (Goldstein & Kleinman, Expert Opin Biol Ther, 2012). It reduces inflammation through downregulation of inflammatory cytokines and supports stem cell differentiation. TB-500 handles the larger-scale remodeling: recruiting new cells, building structural frameworks, modulating the immune response.

Combined, the two peptides address both acute stabilization (BPC-157) and long-term structural repair (TB-500). Animal studies on each peptide individually show accelerated healing of tendons, muscles, and GI tissue. No study has tested the combination directly, but the non-overlapping mechanisms provide a logical basis for stacking.

This is the central question, and the honest answer is: one can, one might not.

Most commercial capsule blends come pre-dosed. The following protocol reflects common community practice and vendor recommendations. No clinical trial has validated these specific oral combination doses.

Typical capsule contents: 500 mcg BPC-157 + 750-1,500 mcg TB-500 per capsule.

Timing: Take capsules in the morning with a small meal to reduce GI side effects from BPC-157. If taking two daily, space them 6-8 hours apart (morning and early afternoon). Avoid evening dosing; BPC-157's dopaminergic effects can disrupt sleep.

Cycle length: 4-8 weeks is the standard community protocol. No data supports continuous use beyond 8 weeks. The washout period allows receptor sensitivity to reset and provides a break from any cumulative effects.

For weight-adjusted dosing and injectable protocols, see our detailed BPC-157 + TB-500 dosage guide. Use the BPC-157 dosage calculator and TB-500 dosage calculator for personalized numbers.

Three options exist for running the BPC-157 + TB-500 combination. Each has distinct advantages.

Best approach for GI healing: Capsule blend. The oral BPC-157 works directly on the gut, and the TB-500 adds potential (if unproven) systemic support.

Best approach for musculoskeletal injury: Separate peptides. Inject TB-500 for confirmed systemic delivery. Take oral BPC-157 for GI support and baseline systemic levels. This hybrid gives you the proven route for each peptide.

Best approach for overall recovery: Injectable blend vial if you are comfortable with injections. Both peptides reach systemic circulation at high bioavailability. See our peptide stacking guide for more combination strategies.

The side effect profile of the capsule blend primarily reflects oral BPC-157, since that component has the stronger evidence base. TB-500-specific oral side effects are poorly documented.

From the BPC-157 component: - Nausea (20-30% of users, first 3-5 days) - Bloating and mild abdominal discomfort (first week) - Loose stools or diarrhea (self-resolving in 5-7 days) - Mild headache (less common than with injectable, ~5-10%) - Appetite changes (variable direction)

For detailed coverage, see our BPC-157 capsule side effects guide.

From the TB-500 component (based on injectable data): - Headache (reported in injectable users, uncertain for oral) - Temporary fatigue or lethargy (first few days) - Mild flu-like symptoms during loading phase - Possible lightheadedness

Combined side effect considerations: the GI side effects from oral BPC-157 are the most likely complaints. TB-500 may contribute additional headache risk if any oral absorption occurs. Users report the first 3-5 days as the adjustment period, with most symptoms resolving by day 7.

For comprehensive stack safety information, see our BPC-157 + TB-500 side effects guide. No serious adverse events have been reported with either peptide in published research. Both peptides lack FDA approval for human use.

The oral peptide supplement market has minimal regulatory oversight. Quality varies widely between vendors. Six factors separate reliable products from questionable ones.

1. Third-party COA (Certificate of Analysis). The vendor should provide a recent COA from an independent lab showing peptide identity (mass spectrometry), purity (>98%), and absence of heavy metals, endotoxins, and microbial contamination. If the COA is from the vendor's own lab, it carries less weight.

2. BPC-157 form specification. The label should state whether the BPC-157 is acetate or arginate. This distinction affects bioavailability by roughly 30x. Vendors who list only "BPC-157" without specifying the salt form may be using the cheaper acetate while implying arginate-level efficacy.

3. TB-500 fragment vs full-length Tb4. Some capsules contain a TB-500 fragment (the active region of Thymosin Beta-4), while others claim to contain full-length Tb4. Full-length Tb4 is 43 amino acids and more expensive to synthesize. The active fragment (17 amino acids) may resist GI degradation better due to its shorter length. Check what the label specifies.

4. Dose per capsule. Look for exact mcg amounts of each peptide. Proprietary blends that list only total milligrams without specifying the ratio make it impossible to assess individual peptide dosing.

5. Capsule type. Enteric-coated capsules resist stomach acid dissolution and release contents in the small intestine. For BPC-157 acetate, this may improve bioavailability. For BPC-157 arginate (already acid-stable), enteric coating is less critical. Standard gelatin capsules dissolve in the stomach.

6. Storage instructions. Peptides degrade with heat and humidity. Products should specify refrigeration or cool, dry storage. Capsules stored at room temperature in a warehouse for months may have reduced potency.

Mistake 1: Expecting injectable-level results from capsules for musculoskeletal injuries. A user takes capsules for 4 weeks to heal a torn rotator cuff and sees minimal improvement. The BPC-157 component is primarily treating the GI tract at the local level (if acetate), and the TB-500 component's systemic delivery is unproven orally. The fix: for localized tissue injuries, inject TB-500 near the site and use oral BPC-157 for complementary support.

Mistake 2: Taking capsules on an empty stomach and quitting due to nausea. The BPC-157 component causes GI discomfort in 20-30% of users when taken without food. A user abandons the protocol after 2 days of nausea. The fix: take capsules with a small meal and allow 5-7 days of adaptation.

Mistake 3: Buying the cheapest capsule without checking the COA. A user purchases a $30 bottle with no third-party testing. The capsules may contain degraded peptide, incorrect doses, or contaminants. Savings of $30-50 are not worth the risk. The fix: buy only from vendors who provide independent lab COAs with mass spectrometry data.

Mistake 4: Running capsule cycles longer than 8 weeks without a break. No safety data supports continuous oral peptide use beyond standard cycle lengths. The fix: follow a 4-8 week cycle with a 2-4 week washout before restarting.